Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Thorax ; 68(6): 506-12, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23457038

ABSTRACT

BACKGROUND: Expression of the T-cell-associated chemokine receptor CCR8 and its ligand CCL1 have been demonstrated to be elevated in patients with asthma. CCR8 deficiency or inhibition in models of allergic airway disease in mice resulted in conflicting data. OBJECTIVE: To investigate the effects of a selective small molecule CCR8 inhibitor (ML604086) in a primate model of asthma. METHODS: ML604086 and vehicle were administered by intravenous infusion to 12 cynomolgus monkeys during airway challenge with Ascaris suum. Samples were collected throughout the study to measure pharmacokinetics (PK) and systemic CCR8 inhibition, as well as inflammation, T helper 2 (Th2) cytokines and mucus in bronchoalveolar lavage (BAL). Airway resistance and compliance were measured before and after allergen challenge, and in response to increasing concentrations of methacholine. RESULTS: ML604086 inhibited CCL1 binding to CCR8 on circulating T-cells>98% throughout the duration of the study. However, CCR8 inhibition had no significant effect on allergen-induced BAL eosinophilia and the induction of the Th2 cytokines IL-4, IL-5, IL-13 and mucus levels in BAL. Changes in airway resistance and compliance induced by allergen provocation and increasing concentrations of methacholine were also not affected by ML604086. CONCLUSIONS: These results clearly demonstrate a dispensable role for CCR8 in ameliorating allergic airway disease in atopic primates, and suggest that strategies other than CCR8 antagonism should be considered for the treatment of asthma.


Subject(s)
Airway Resistance/physiology , Asthma/immunology , Biological Factors/pharmacokinetics , Receptors, CCR8/antagonists & inhibitors , Th2 Cells/immunology , Animals , Asthma/metabolism , Asthma/physiopathology , Biological Factors/administration & dosage , Bronchoalveolar Lavage Fluid/chemistry , Chemokine CCL1/antagonists & inhibitors , Chemokine CCL1/biosynthesis , Chemokine CCL1/immunology , Disease Models, Animal , Female , Infusions, Intravenous , Lung/drug effects , Lung/physiopathology , Lung Compliance , Macaca fascicularis , Male , Receptors, CCR8/biosynthesis , Receptors, CCR8/immunology , Th2 Cells/metabolism
2.
Mol Cancer Ther ; 6(1): 262-8, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17237285

ABSTRACT

Poh1 deubiquitinase activity is required for proteolytic processing of polyubiquitinated substrates by the 26S proteasome, linking deubiquitination to complete substrate degradation. Poh1 RNA interference (RNAi) in HeLa cells resulted in a reduction in cell viability and an increase in polyubiquitinated protein levels, supporting the link between Poh1 and the ubiquitin proteasome pathway. To more specifically test for any requirement of the zinc metalloproteinase motif of Poh1 to support cell viability and proteasome function, we developed a RNAi complementation strategy. Effects on cell viability and proteasome activity were assessed in cells with RNAi of endogenous Poh1 and induced expression of wild-type Poh1 or a mutant form of Poh1, in which two conserved histidines of the proposed catalytic site were replaced with alanines. We show that an intact zinc metalloproteinase motif is essential for cell viability and 26S proteasome function. As a required enzymatic component of the proteasome, Poh1 is an intriguing therapeutic drug target for cancer.


Subject(s)
Proteasome Endopeptidase Complex/chemistry , Proteasome Endopeptidase Complex/metabolism , Trans-Activators/chemistry , Trans-Activators/metabolism , Ubiquitin/metabolism , Amino Acid Motifs , Cell Survival , HeLa Cells , Humans , Mutant Proteins/metabolism , Proteasome Endopeptidase Complex/deficiency , RNA Interference , Trans-Activators/deficiency
3.
Assay Drug Dev Technol ; 4(6): 661-9, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17199504

ABSTRACT

Adenine phosphoribosyltransferase plays a role in purine salvage by catalyzing the direct conversion of adenine to adenosine monophosphate. The involvement of the purine salvage pathway in tumor proliferation and angiogenesis makes adenine phosphoribosyltransferase a potential target for oncology drug discovery. We have expressed and characterized recombinant, N-terminally His-tagged human adenine phosphoribosyltransferase. Two assay formats were assessed for use in a high throughput screen: a spectrophotometric-based enzyme-coupled assay system and a radiometric ionic capture scintillation proximity bead assay format. Ultimately, the scintillation proximity assay format was chosen because of automated screening compatibility limitations of the coupled assay. We describe here the biochemical characterization of adenine phosphoribosyltransferase and the development of a robust, homogeneous, 384-well assay suitable for high throughput screening.


Subject(s)
Adenine Phosphoribosyltransferase/metabolism , Scintillation Counting/methods , Adenine/metabolism , Adenine Phosphoribosyltransferase/antagonists & inhibitors , Adenylate Kinase/metabolism , Humans , L-Lactate Dehydrogenase/metabolism , NAD/metabolism , Pyruvate Kinase/metabolism , Recombinant Proteins/metabolism , Tritium
4.
Prostaglandins Other Lipid Mediat ; 76(1-4): 133-47, 2005 May.
Article in English | MEDLINE | ID: mdl-15967168

ABSTRACT

Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2), a G protein-coupled receptor activated by prostaglandin D(2) (PGD(2)), has been identified as a receptor expressed on cell types critical to the pathogenesis of asthma. The cDNA encoding guinea pig CRTH2 was cloned and mRNA expression examined in selected tissues. Transcript profiling of guinea pig CRTH2 indicated relatively high levels of expression in bone marrow, intermediate levels in brain and relatively low levels in lung, spleen, thymus, lymph node, etc. Characterization of the molecular pharmacology of guinea pig CRTH2 revealed that guinea pig CRTH2 exhibited a greater affinity for Delta(12)-PGJ(2), a stable PGD(2) metabolite relative to human CRTH2. The CRTH2 selective agonists 13,14-dihydro-15-keto PGD(2) and Delta(12)-PGJ(2) induced the recruitment of eosinophils following intradermal administration of these ligands in guinea pigs. Chemotaxis of guinea pig eosinophils was elicited by either PGD(2) or Delta(12)-PGJ(2), and was abolished by a CRTH2-specific antagonist. These results indicate that PGD(2) and the stable metabolite, Delta(12)-PGJ(2), play important roles in CRTH2 activation in the guinea pig.


Subject(s)
Receptors, Immunologic/metabolism , Receptors, Prostaglandin/metabolism , Animals , Base Sequence , Calcium/metabolism , Cell Line , Chemotaxis, Leukocyte , Cloning, Molecular , DNA Primers , DNA, Complementary , Eosinophils/cytology , Guinea Pigs , Humans , Lung/metabolism , Lymph Nodes/metabolism , Male , Receptors, Immunologic/genetics , Receptors, Prostaglandin/genetics , Spleen/metabolism , Thymus Gland/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...